BISMUTH TARTRATE ANHYDROUS

US Previously Marketed

[Bi+3].[Bi+3].O[C@H]([C@@H](O)C([O-])=O)C([O-])=O.O[C@H]([C@@H](O)C([O-])=O)C([O-])=O.O[C@H]([C@@H](O)C([O-])=O)C([O-])=O

InChIKey=SULICOHAQXOMED-YDXPQRMKSA-H

InChI=1S/3C4H6O6.2Bi/c3*5-1(3(7)8)2(6)4(9)10;;/h3*1-2,5-6H,(H,7,8)(H,9,10);;/q;;;2*+3/p-6/t3*1-,2-;;/m111../s1

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Bismuth tartrate was used for the treatment of syphilis. There are death reports associated with bismuth compounds usage in syphilis treatment.

Doses

Dose	Population	Adverse events
0.5 g 1 times / 2 weeks multiple, intravenous Studied dose Dose: 0.5 g, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 0.5 g, 1 times / 2 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/13058286/	unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/13058286/	Other AEs: Nephrotic syndrome... Other AEs: Nephrotic syndrome Sources: https://pubmed.ncbi.nlm.nih.gov/13058286/
650 mg 1 times / day single, intravenous Studied dose Dose: 650 mg, 1 times / day Route: intravenous Route: single Dose: 650 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18867938/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18867938/	Other AEs: Death... Other AEs: Death Sources: https://pubmed.ncbi.nlm.nih.gov/18867938/

AEs

AE	Significance	Dose	Population
Nephrotic syndrome		0.5 g 1 times / 2 weeks multiple, intravenous Studied dose Dose: 0.5 g, 1 times / 2 weeks Route: intravenous Route: multiple Dose: 0.5 g, 1 times / 2 weeks Sources: https://pubmed.ncbi.nlm.nih.gov/13058286/	unhealthy, 39 years Health Status: unhealthy Age Group: 39 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/13058286/
Death		650 mg 1 times / day single, intravenous Studied dose Dose: 650 mg, 1 times / day Route: intravenous Route: single Dose: 650 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18867938/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/18867938/

Sourcing

Vendor/Aggregator	ID	URL
AAA Chemistry	AR-1I0637
ABI Chem	AC1L35JZ
ABI Chem	AC1LAIJC
Amadis Chemical	A11654
Ambinter	Amb22730412	http://www.ambinter.com/reference/22730412
ChemIDplus	31586773	https://chem.nlm.nih.gov/chemidplus/id/0031586773
ChemTik	CTK4G7397
DTP/NCI	302012	http://dtp.nci.nih.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=302012
MP Biomedicals	212309
NovoSeek	134954
PubChem	134954	https://pubchem.ncbi.nlm.nih.gov/compound/134954
PubChem	469103	https://pubchem.ncbi.nlm.nih.gov/compound/469103
PubChem	54600498	https://pubchem.ncbi.nlm.nih.gov/compound/54600498
PubChem	76971117	https://pubchem.ncbi.nlm.nih.gov/compound/76971117
Wikidata	Q27279003

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:57:54 GMT 2025` Edited by `admin` on `Mon Mar 31 17:57:54 GMT 2025`
Record UNII	DKV172B7RB
Record Status	`Validated (UNII)`
Record Version

Name

Type

Language

BUTANEDIOIC ACID, 2,3-DIHYDROXY- (2R,3R)-, BISMUTH(3+) SALT (3:2)

Preferred Name

English

BISMUTH TARTRATE ANHYDROUS

Common Name

English

DIBISMUTH TRITARTRATE

Systematic Name

English

TARTARIC ACID, BISMUTH SALT (3:2)

Systematic Name

English

BUTANEDIOIC ACID, 2,3-DIHYDROXY-(R-(R*,R*))-, BISMUTH(3+) SALT (3:2)

Systematic Name

English

Code System Code Type Description

ECHA (EC/EINECS)

229-530-2